Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit

PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that a federal judge in Delaware has dismissed all claims...
October 07, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Director Dr. William Mitchell to Present Research on Treating Deadly Emerging Viruses During the 4th World Congress on Virology October 8

PHILADELPHIA, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Dr. William Mitchell, Ph.D., a Professor of Pathology, Microbiology and Immunology at Vanderbilt University who also serves as a Director with Hemispherx...
September 29, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators

PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
September 22, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus

PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
September 15, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans

PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...
September 10, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it expanded its Collaborative Research Agreement to test...
September 08, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
September 03, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th

PHILADELPHIA, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global...
August 11, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014

PHILADELPHIA, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the six months ended June 30, 2014. The net loss (including non-cash effects) was...
August 04, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses

PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...